Clinical UM Guideline

This document addresses the medical necessity criteria for standard lipid panel testing. A standard lipid panel includes total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, and calculated low-density lipoprotein cholesterol (LDL-C). Direct LDL-C measurement may be performed in specific clinical circumstances addressed in this document.

Note: For a high-level overview of this document, please see “Summary for Members and Families” below.

Medically Necessary:

I.  Diagnostic and Therapeutic Management Testing

Standard lipid panel testing is considered medically necessary for diagnostic or therapeutic management purposes when any of the following criteria (A through F) are met:

1. The individual has one or more of the following conditions:
   1. Diabetes mellitus; or
   2. Chronic kidney disease; or
   3. Hypertension; or
   4. Metabolic syndrome; or
   5. Chronic inflammatory disease (for example, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, inflammatory bowel disease); or
   6. Family history of premature atherosclerotic cardiovascular disease (ASCVD), as indicated by both of the following criteria:
      1. Early onset ASCVD in a first-degree relative, defined as one of the following:
         1. History of a cardiovascular event in a male first-degree relative before age 55; or
         2. History of a cardiovascular event in a female first-degree relative before age 65; and
      2. Cascade screening for familial hypercholesterolemia has not previously been performed;
         or
2. The individual has an abnormal prior lipid test result requiring follow-up; or
3. There is clinical suspicion of dyslipidemia based on signs, symptoms, or physical findings (for example, xanthomas, xanthelasma, lipemia retinalis, eruptive xanthomas); or
4. The individual has a diagnosis of dyslipidemia, familial hypercholesterolemia, or other lipid disorder; or
5. The individual has a history of pancreatitis or triglycerides greater than or equal to 500 milligrams per deciliter (mg/dL) requiring monitoring; or
6. The individual has established atherosclerotic cardiovascular disease, including coronary artery disease, history of myocardial infarction, cerebrovascular disease (stroke or transient ischemic attack), or peripheral arterial disease.

Frequency Limitations for Section I:

1. For diagnostic evaluation: Up to 2 tests within a 3-month period, with tests performed at least 2 weeks apart.
2. Monitoring the effects of drugs associated with secondary dyslipidemia (for example, Janus kinase inhibitors, interleukin-6 inhibitors, isotretinoin, or antiretroviral therapy) (see discussion):
   1. For individuals initiating or adjusting therapy:
      1. Testing 4 to 12 weeks following therapy initiation or dose adjustment, then
      2. Every 6 to 12 months for stable therapy monitoring.
   2. For individuals requiring no change in therapy with a stable lipid response and no clinical changes, testing every 12 months. 
3. Testing frequency during active management should be individualized based on severity of hypertriglyceridemia.
4. For severe hypertriglyceridemia (triglycerides greater than or equal to 500 mg/dL or history of triglyceride-induced pancreatitis) or chylomicronemia (triglycerides greater than or equal to 1000 mg/dL indicating very high pancreatitis risk), testing frequency during active management should be individualized based on severity of hypertriglyceridemia.
5. For pregnancy-related testing in high-risk individuals: Testing each trimester with additional testing when triglycerides exceed 250 mg/dL in the third trimester; postpartum reassessment at 6 to 12 weeks.

Note: A nonfasting lipid panel is acceptable for screening purposes and for most diagnostic and monitoring purposes. Fasting is not required unless triglyceride measurement will directly guide treatment decisions.

II.  Screening Testing

Standard lipid panel testing for screening purposes (that is, in asymptomatic individuals without a diagnosis of dyslipidemia, signs, symptoms, or abnormal prior results) is considered medically necessary when performed according to the following intervals:

1. Universal Pediatric Screening:
   1. Once between ages 9 and 11 years old;
      or
2. Selective Pediatric Screening (starting at 2 years of age):
   Testing for children and adolescents outside universal screening ages when one or more of the following are present:
   1. First- or second-degree relative with premature atherosclerotic cardiovascular disease, severe hypercholesterolemia, or familial hypercholesterolemia, for the purpose of cascade screening to identify familial hypercholesterolemia; or
   2. Family history of premature cardiovascular disease, defined as cardiovascular event in male first-degree relative before age 55 or female first-degree relative before age 65; or
   3. Family history of dyslipidemia or known familial hypercholesterolemia; or
   4. Overweight or obesity defined as body mass index greater than or equal to the 85th percentile for age and sex; or
   5. High-risk medical condition, including but not limited to diabetes, hypertension, chronic kidney disease, Kawasaki disease with coronary aneurysms, chronic inflammatory disease, HIV infection, or nephrotic syndrome;
      or
3. Adult Screening (age 19 years and older):
   1. Lipid testing beginning at age 19 years, at least once every 4 to 6 years for individuals without additional ASCVD risk factors, with more frequent screening with increasing age or additional risk factors.

III.  Direct LDL-C Testing

Direct LDL-C measurement (in lieu of LDL-C estimated by the Martin/Hopkins or Sampson/NIH equation) is considered medically necessary when either criteria A or B are met:

1. Conditions where LDL-C estimation is not valid or reliable, including any of the following:
   1. Triglycerides greater than or equal to 400 mg/dL; or
   2. Suspected or confirmed Type III Hyperlipoproteinemia (familial dysbetalipoproteinemia); or
   3. Calculated LDL-C is reported as invalid or unreliable by the laboratory, including but not limited to:
      1. Markedly elevated triglycerides (including nonfasting samples); or
      2. Assay interference; or
      3. Inability to perform or report a validated calculation method;
         or
2. Conditions where precise LDL-C measurement is required for clinical decision-making, direct LDL-C measurement is considered medically necessary when all of the following are met:
   1. Calculated LDL-C is within a very low range (for example, less than 55 to 70 mg/dL); and
   2. Accurate LDL-C quantification is required to guide high-risk treatment decisions (for example, escalation or de-escalation of lipid-lowering therapy); and
   3. Preferred calculation methods (Martin/Hopkins or Sampson/NIH) are unavailable or reported as unreliable in the specific clinical context.

Not Medically Necessary:

Standard lipid panel testing is considered not medically necessary for any of the following:

1. Diagnostic or therapeutic monitoring testing when criteria above are not met; or
2. Screening in asymptomatic individuals performed more frequently than the intervals specified above; or
3. Repeat diagnostic or monitoring testing performed sooner than the frequency limits specified above without documented clinical indication; or
4. Direct LDL-C measurement when criteria for Direct LDL-C Testing (Section III) are not met.

This document describes clinical studies and expert recommendations, and explains whether standard lipid panel testing is clinically appropriate. The following summary does not replace the medical necessity criteria or other information in this document. The summary may not contain all of the relevant criteria or information. This summary is not medical advice. Please check with your healthcare provider for any advice about your health.

Key Information

A standard lipid panel is a blood test that checks the level of different types of fats in the blood. It tells the doctor the amounts of total cholesterol, high-density lipoprotein (HDL) or “good” cholesterol, low-density lipoprotein (LDL) or “bad” cholesterol, and triglycerides, which are another kind of fat. Most of the time, the laboratory calculates LDL from the other numbers using a math equation; sometimes, the laboratory measures LDL directly. Doctors use these results to find and treat problems that can lead to heart disease and other conditions. A lipid panel can be ordered to look for problems in healthy people who have no symptoms, to confirm a problem in people who have symptoms, or to see if treatment for high blood lipid levels is working. How often you need the test depends on your age, your health, and your risk factors. People with very high triglycerides or a very high risk of heart trouble may need the direct LDL test instead of the calculated kind.

What the Studies Show

For routine screening, children should have 1 test between ages 9 and 11. Children and adolescents starting at age 2 should also be tested outside universal screening ages if there is early heart disease in the family, a lipid disorder that runs in the family, a body mass index at or above the 85th percentile, or a high-risk health condition such as diabetes, kidney disease, or human immunodeficiency virus (HIV). Adults who are 19 years old or older and have no risk factors should be tested every 4 to 6 years. Direct LDL testing is helpful when triglycerides are 400 milligrams per deciliter (mg/dL) or higher; when triglycerides are above 250 mg/dL in certain high-risk situations, including diabetes; when a very low LDL number needs confirmation; when the calculated LDL number is unreliable; or when a very precise LDL number is needed for treatment decisions.

When Is This Not Clinically Appropriate?

A standard lipid panel or a direct LDL test is not needed when screening is repeated sooner than recommended without a clear medical reason. It is also not needed when direct LDL testing is ordered for someone who does not meet the special conditions listed above.

(Return to Description)

The following codes for treatments and procedures applicable to this guideline are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Panel testing
When services are Medically Necessary:

When services may be Medically Necessary when criteria are met:
For the procedure code listed above for all other diagnoses including but not limited to those listed below:

When services are Not Medically Necessary:
For the procedure code listed above when criteria are not met or for situations designated in the Clinical Indications section as not medically necessary.

Direct LDL-C
When services may be Medically Necessary when criteria are met:

When services are Not Medically Necessary:
For the procedure code listed above when criteria are not met or for situations designated in the Clinical Indications section as not medically necessary.

Summary

Lipid testing is central to the assessment, diagnosis, and longitudinal management of atherosclerotic cardiovascular disease (ASCVD). The evidence reviewed in this section supports targeted screening across pediatric and adult populations, with universal pediatric screening at ages 9 to 11 and periodic adult reassessment beginning in early adulthood. Diagnostic and therapeutic testing is indicated in individuals with conditions linked to elevated ASCVD risk or altered lipid metabolism, with monitoring intervals calibrated to treatment response and disease course. Contemporary methodology favors validated calculation methods for routine low-density lipoprotein cholesterol (LDL-C) measurement, reserving direct LDL-C measurement for circumstances in which estimation is unreliable.

Discussion

I. Diagnostic and Therapeutic Management Testing

Clinical scenarios in which lipid testing directly informs medical decision-making include:

1. High-risk conditions:
   1. Conditions such as diabetes mellitus, chronic kidney disease, hypertension, metabolic syndrome, and chronic inflammatory diseases are consistently associated with increased ASCVD risk and characteristic lipid abnormalities. Testing in these populations is necessary to guide risk stratification and treatment intensity (Grundy, 2019; Jellinger, 2017).
   2. Family history criteria and cascade screening support the identification of inherited disorders such as familial hypercholesterolemia, where early detection alters outcomes.
2. Abnormal prior results: Follow-up testing is required to confirm abnormalities, assess persistence, and guide further evaluation or treatment.
3. Clinical suspicion: Physical findings such as xanthomas or lipemia retinalis are manifestations of underlying lipid disorders, warranting diagnostic confirmation through laboratory testing.
4. Established lipid disorders: Ongoing testing is essential for management of dyslipidemia, including monitoring response to therapy and disease progression.
5. Severe hypertriglyceridemia or pancreatitis risk: Triglyceride levels greater than or equal to 500 milligrams per deciliter (mg/dL) are associated with pancreatitis risk, necessitating close monitoring and treatment adjustment (Virani, 2021).
6. Established ASCVD: In secondary prevention, lipid levels guide treatment intensification and are directly linked to reduction in recurrent cardiovascular events (Blumenthal, 2026; Grundy, 2019).

Frequency limits are based on lipid kinetics and treatment response:

1. Short-term repeat testing (2 weeks to 3 months) supports diagnostic confirmation and early treatment assessment.
2. Reassessment at 4 to 12 weeks after therapy initiation or adjustment reflects the time required to reach a new steady state.
3. Long-term monitoring intervals (6 to 12 months) balance the need for ongoing assessment with avoidance of unnecessary testing (Blumenthal, 2026; Grundy, 2019).
4. More intensive monitoring for severe hypertriglyceridemia reflects variable clinical risk and the need to prevent pancreatitis.

The allowance for nonfasting testing reflects evidence that most lipid parameters are minimally affected by fasting, reserving fasting for cases where triglycerides influence management (Cao, 2024).

II. Screening

Screening criteria reflect a balance between early detection and evidence limitations:

1. Universal pediatric screening (ages 9 to 11) targets a period of physiologic stability and supports detection of familial hypercholesterolemia and early dyslipidemia (Blumenthal, 2026; National Heart, Lung, and Blood Institute, 2012).
2. Selective pediatric screening (starting at age 2) is based on risk factors associated with early lipid abnormalities, including family history, obesity, and high-risk medical conditions. Cascade screening is specifically supported to identify inherited lipid disorders. The U.S. Preventive Services Task Force notes that evidence for universal pediatric screening is uncertain, supporting a targeted, risk-based approach (U.S. Preventive Services Task Force, 2023).
3. Adult screening (≥ 19 years) recognizes the progressive nature of ASCVD risk and the high prevalence of undiagnosed dyslipidemia. Periodic testing every 4 to 6 years in low-risk individuals, with more frequent assessment as risk increases, aligns with guideline-based longitudinal risk evaluation (Blumenthal, 2026; Grundy, 2019).

III. Direct LDL-C Testing

Current best practices in LDL-C measurement include:

Preference for the method to calculate LDL-C levels: The Martin/Hopkins and Sampson/NIH equations provide more accurate LDL-C estimation across a wide range of triglyceride and LDL-C levels compared with the historically used Friedewald equation (Cao, 2024; Blumenthal, 2026).

1. Indications for direct LDL-C measurement: Direct measurement is reserved for situations in which estimation is invalid or unreliable, including triglycerides ≥400 mg/dL, Type III hyperlipoproteinemia, or laboratory-reported calculation limitations.
2. High-precision decision-making: In select high-risk individuals with very low LDL-C levels, precise quantification may be required to guide therapy adjustments when calculation methods are unavailable or unreliable.

This approach avoids unnecessary use of direct LDL-C testing while ensuring accuracy when it is clinically required.

Testing is not medically necessary when it does not inform clinical management, including testing outside defined clinical indications:

1. Screening performed more frequently than recommended intervals;
2. Repeat testing without sufficient time for biologic change; or
3. Use of direct LDL-C measurement when validated estimation methods are appropriate.

These limitations are supported by evidence emphasizing appropriate utilization, avoidance of overtesting, and alignment of testing frequency with clinical need (Grundy, 2019; Blumenthal, 2026).

The criteria are supported by contemporary guideline recommendations and evidence demonstrating that lipid testing is medically necessary when it informs ASCVD risk assessment, diagnosis, treatment selection, and monitoring, while avoiding unnecessary testing in low-value scenarios.

Evolution of Lipid Management and Testing (2018-2026)

The approach to lipid management has evolved from a focus on short-term ASCVD risk estimation to a model emphasizing cumulative exposure to atherogenic lipoproteins and earlier, sustained intervention. The 2018 American Heart Association (AHA) and American College of Cardiology (ACC) guideline emphasized risk stratification and statin-based treatment (Grundy, 2019). Subsequent guidance expanded the role of risk-enhancing factors, such as elevated triglycerides, and reinforced the importance of comprehensive lipid assessment (Virani, 2021).

The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) similarly emphasized risk-based low-density lipoprotein cholesterol (LDL-C) targets and more aggressive lipid lowering in higher-risk populations, based on evidence demonstrating incremental benefit with lower LDL-C levels (Jellinger, 2017).

More recent recommendations further emphasize routine screening, structured monitoring, and treatment intensification, supporting lipid testing as an ongoing component of clinical management rather than a single assessment (Blumenthal, 2026).

Clinical Role of Lipid Testing

Accurate lipid measurement is central to ASCVD risk assessment and management. A standard lipid panel includes total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides, with calculation of LDL-C and non-HDL cholesterol. These parameters provide a comprehensive assessment of atherogenic lipoprotein burden (Cao, 2024).

Dyslipidemia is typically asymptomatic but is a well-established, modifiable risk factor for ASCVD. Clinical trial evidence demonstrates that lowering LDL-C reduces cardiovascular events, supporting lipid testing as medically necessary when it informs risk assessment or treatment decisions (Blumenthal, 2026; Grundy, 2019).

Screening in Asymptomatic Individuals

Pediatric Population

Recommendations for screening of children are based on evidence that lipid abnormalities, including familial hypercholesterolemia and multifactorial dyslipidemia, can begin early in life and contribute to premature ASCVD (U.S. Preventive Services Task Force, 2023).

The U.S. Preventive Services Task Force (USPSTF) concludes that evidence is insufficient to determine the balance of benefits and harms of universal screening in asymptomatic children, reflecting ongoing uncertainty regarding optimal screening strategies (U.S. Preventive Services Task Force, 2023).

These findings support a policy approach that prioritizes targeted and guideline-aligned screening in higher-risk populations.

Adult Population

In adults, dyslipidemia is common and frequently undiagnosed. Screening beginning in early adulthood with periodic reassessment is supported by the progressive nature of ASCVD risk and the need for longitudinal risk evaluation (Blumenthal, 2026; Grundy, 2019).

Diagnostic and Therapeutic Management Testing

Lipid testing is medically necessary in individuals with clinical conditions associated with increased ASCVD risk or altered lipid metabolism. These include diabetes mellitus, hypertension, chronic kidney disease, metabolic syndrome, and chronic inflammatory diseases. These conditions are associated with higher ASCVD risk and characteristic lipid abnormalities, including elevated triglycerides and atherogenic lipoprotein patterns (Jellinger, 2017).

Testing is also necessary for:

• Follow-up of abnormal prior results;
• Evaluation of clinical signs or suspected lipid disorders;
• Management of known dyslipidemia; and
• Secondary prevention in individuals with established ASCVD.

Elevated triglycerides are recognized as independent risk markers and risk-enhancing factors. Severe hypertriglyceridemia, defined as triglycerides greater than or equal to 500 mg/dL, is associated with an increased risk of pancreatitis and requires active monitoring and management (Virani, 2021).

In each of these contexts, lipid testing directly informs clinical decision-making and is therefore medically necessary.

Monitoring and Frequency of Testing

Testing intervals are based on the expected response to therapy and the clinical course of lipid disorders. Lipid levels typically reach a new steady state within several weeks after therapy initiation or adjustment, supporting repeat testing within this timeframe to assess treatment response and adherence (Blumenthal, 2026; Grundy, 2019).

Once stable, periodic monitoring at longer intervals is appropriate to confirm continued control and identify clinically meaningful changes. Monitoring frequency should be individualized based on overall risk, treatment intensity, and clinical status rather than performed routinely without indication (Jellinger, 2017).

Some non-lipid-lowering therapies are associated with clinically meaningful lipid changes and may require lipid testing after initiation or therapy adjustment. In inflammatory disease populations, tofacitinib and tocilizumab have been associated with increases in lipid parameters during clinical studies, supporting lipid reassessment after starting therapy. Isotretinoin therapy has also been associated with triglyceride and cholesterol abnormalities, with evidence supporting early follow-up testing after initiation in appropriate individuals. In people with human immunodeficiency virus (HIV), federal antiretroviral guidelines recommend lipid screening at entry to care or at antiretroviral therapy initiation or modification, with follow-up after therapy initiation to inform cardiovascular risk assessment and management (Gladman, 2019; Hansen, 2016; Panel on Antiretroviral Guidelines for Adults and Adolescents, 2025; Schiff, 2011).

Fasting and Nonfasting Testing

Nonfasting lipid testing is appropriate for most screening and monitoring purposes. Total cholesterol and HDL-C levels are minimally affected by fasting status, and postprandial changes in triglycerides are generally modest in most individuals (Cao, 2024).

Fasting testing is reserved for situations in which triglyceride levels will directly affect clinical decision-making, including evaluation of significant hypertriglyceridemia or confirmation of abnormal results.

LDL-C Estimation and Direct Measurement

Historically, LDL-C has been estimated using the Friedewald equation, which calculates LDL-C from total cholesterol, HDL-C, and triglycerides. This method has been widely used in clinical practice but has known limitations, particularly in individuals with elevated triglycerides, low LDL-C levels, or nonfasting samples, in which it may underestimate LDL-C (Cao, 2024).

More recently, alternative estimation methods, including the Martin/Hopkins equation and the Sampson/National Institutes of Health (NIH) equation, have been developed to improve accuracy across a broader range of lipid values. These methods adjust for variability in triglyceride-rich lipoproteins and provide more reliable LDL-C estimates, particularly when triglycerides are elevated or LDL-C is low (Blumenthal, 2026; Cao, 2024).

Current guidance supports the use of the Martin/Hopkins or Sampson/National Institutes of Health (NIH) equations as the preferred methods for LDL-C estimation in most clinical scenarios. Direct LDL-C measurement is reserved for situations in which estimation is not valid or reliable, including triglyceride levels of at least 400 mg/dL or specific dyslipidemias affecting lipoprotein composition (Blumenthal, 2026).

Direct LDL-C measurement is not routinely necessary and is reserved for specific clinical circumstances in which estimation is not valid or reliable. These include:

• Triglycerides of at least 400 mg/dL;
• Disorders affecting lipoprotein composition; or
• Laboratory-reported invalid or unreliable calculated LDL-C values.

Atherogenic lipoproteins: Plasma lipoproteins that contain apolipoprotein B (apoB) and are causally linked to the initiation and progression of atherosclerosis. This category includes low-density lipoproteins (LDL), very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), chylomicron remnants, and lipoprotein(a) [Lp(a)]. Each atherogenic particle contains 1 molecule of apoB (either apoB-100 or apoB-48), making apoB measurement a direct quantification of total atherogenic particle number (Blumenthal, 2026).

Atherosclerotic cardiovascular disease (ASCVD): Clinical conditions caused by atherosclerosis, including coronary heart disease, cerebrovascular disease, and peripheral arterial disease. These conditions define high-risk populations and guide secondary prevention strategies.

Calculated low-density lipoprotein cholesterol (LDL-C): Low-density lipoprotein cholesterol estimated from a standard lipid panel using validated equations, including the Martin/Hopkins or Sampson/National Institutes of Health methods, which are preferred over the Friedewald equation in most clinical circumstances.

Cascade screening: The systematic process of identifying, contacting, and testing at-risk blood relatives of an individual (the proband or index case) who has been diagnosed with a hereditary condition, typically through genetic counseling and testing or disease-specific screening. The term "cascade" reflects the expanding circles of testing that radiate outward from the proband to first-degree relatives, then to second- and third-degree relatives in successive waves.

Chronic inflammatory disease: A pathological condition characterized by persistent inflammatory processes beyond their physiological function, resulting in ongoing tissue damage and attempts at repair. Unlike acute inflammation, chronic inflammatory diseases are marked by infiltration of affected tissues with mononuclear cells (macrophages, lymphocytes, plasma cells), sustained activation of immune pathways, and simultaneous tissue destruction and remodeling. These conditions arise from either persistent injurious stimuli or, more commonly, dysregulated immune responses that fail to resolve, leading to excessive inflammatory signals or impairment of pro-resolving pathways. Chronic inflammatory diseases encompass a broad spectrum of disorders including autoimmune conditions (rheumatoid arthritis, inflammatory bowel disease), metabolic diseases (diabetes, atherosclerosis), neurodegenerative disorders, and certain malignancies, all sharing the common feature of unresolved, low-grade inflammation that persists for months to years.

Chylomicronemia: A metabolic state defined by fasting triglycerides greater than or equal to 10 millimoles per liter (mmol/L) (greater than or equal to 885 milligrams per deciliter [mg/dL]), often operationalized as 1000 mg/dL, with pathological accumulation of chylomicrons in plasma. When accompanied by clinical manifestations such as abdominal pain, acute pancreatitis, eruptive xanthomas, lipemia retinalis, hepatosplenomegaly, or visibly lipemic plasma, the condition is termed “chylomicronemia syndrome.”

Direct LDL-C: LDL cholesterol measured directly using laboratory methods rather than estimation; reserved for clinical scenarios in which calculated LDL-C is invalid or unreliable.

Dyslipidemia: Abnormal lipid levels, including elevated total cholesterol, elevated LDL-C, elevated triglycerides, low HDL-C, or other atherogenic lipid abnormalities associated with increased ASCVD risk.

Familial hypercholesterolemia (FH): A genetic disorder causing severely elevated LDL-C from birth and increased risk of premature ASCVD, for which early identification through cascade screening and treatment is recommended.

Friedewald equation: A historical method for estimating LDL-C from a fasting lipid panel using the formula:

LDL-C = Total Cholesterol − HDL-C − (Triglycerides ÷ 5)

Accuracy is limited in individuals with triglycerides ≥ 400 mg/dL, low LDL-C levels, or nonfasting samples. Current guidelines prefer the Martin/Hopkins or Sampson/National Institutes of Health equations.

Lipid-lowering therapy: Interventions used to reduce levels of atherogenic lipoproteins, particularly low-density lipoprotein cholesterol, to decrease atherosclerotic cardiovascular disease risk; includes pharmacologic treatments (such as statins and nonstatin agents) and therapeutic lifestyle modifications.

Martin/Hopkins equation: A validated method for estimating LDL-C from a standard lipid panel that uses an adjustable triglyceride-to-VLDL-C ratio, providing improved accuracy across a wide range of triglyceride and LDL-C levels.

Metabolic syndrome: A cluster of interrelated cardiovascular and metabolic risk factors that occur together more frequently than by chance alone, including central obesity, dyslipidemia, elevated blood pressure, and insulin resistance or glucose intolerance. Diagnosis requires three or more of the following five criteria:

1. Elevated waist circumference (≥ 102 cm in men, ≥ 88 cm in women; population-specific cutoffs may apply),
2. Elevated triglycerides (≥ 150 mg/dL or on therapy),
3. Reduced HDL cholesterol (< 40 mg/dL in men, < 50 mg/dL in women, or on therapy),
4. Elevated blood pressure (≥ 130/85 mm Hg or on antihypertensive therapy), and
5. Elevated fasting glucose (≥ 100 mg/dL or on therapy).

Individuals with metabolic syndrome have approximately twice the risk of cardiovascular disease over 5 to 10 years and 5 times the risk of type 2 diabetes compared with individuals without metabolic syndrome.

Nonfasting lipid testing: Lipid panel performed without fasting; acceptable for initial screening and many monitoring purposes per current guidelines. Fasting levels are reserved for evaluation of hypertriglyceridemia or when triglyceride levels will guide management.

Non-high-density lipoprotein cholesterol (non-HDL-C): Total cholesterol (TC) minus high-density lipoprotein cholesterol (HDL-C), representing a composite measure of the cholesterol content of all atherogenic lipoproteins. This calculation can be performed at no additional cost from a standard lipid profile and does not require fasting.

Primary prevention: Interventions designed to modify adverse levels of risk factors in individuals without clinically apparent disease, with the goal of preventing an initial disease event or injury from occurring. Primary prevention targets individuals who have risk factors for disease but no clinical evidence of the disease itself, distinguishing it from primordial prevention (which prevents risk factors from developing in the first place) and secondary prevention (which controls disease progression once present).

Sampson/National Institutes of Health (NIH) equation: A validated method for estimating LDL-C that incorporates triglyceride levels and nonlinear relationships in lipoprotein metabolism, with improved accuracy in individuals with hypertriglyceridemia. Along with the Martin/Hopkins equation, it is preferred over the Friedewald equation per the 2026 American College of Cardiology/American Heart Association (ACC/AHA) guideline.

Screening: Testing performed in asymptomatic individuals to detect risk factors or undiagnosed conditions.

Secondary prevention: Interventions aimed at controlling disease progression in individuals with established disease or detectable abnormalities, with the goal of preventing further clinical events, complications, or worsening of the condition. This level of prevention targets individuals who already have clinically apparent disease or anatomic evidence of disease (such as atherosclerosis) and seeks to reduce the risk of recurrent events and mortality.

Standard lipid panel: A blood test measuring total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides, with calculated low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol.

Steady state (lipid response): The point at which lipid levels have stabilized following initiation or adjustment of lipid-lowering therapy, reflecting the full pharmacologic effect of the medication. For statins, therapeutic response begins within 2 weeks, with maximum LDL-C reduction typically achieved within 4 weeks and maintained during chronic therapy.

Triglyceride (TG): Lipid esters formed when three fatty acids are combined with a three-carbon glycerol molecule (also called triacylglycerol). The plasma triglyceride concentration encompasses the triglyceride content of all lipoprotein particles, including chylomicrons, very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and, to a lesser extent, low-density lipoprotein (LDL) and high-density lipoprotein (HDL).

• Normal fasting triglyceride level is less than 150 mg/dL.
• Moderate elevation of triglycerides: Triglyceride levels of 200 to 499 mg/dL. This range is associated with increased atherosclerotic cardiovascular disease (ASCVD) risk, primarily due to elevated VLDL and remnant lipoproteins.
• Severe hypertriglyceridemia: Triglyceride levels greater than or equal to 500 mg/dL. At this threshold, the risk of acute pancreatitis becomes a primary clinical concern in addition to ASCVD risk.

Type III hyperlipoproteinemia (familial dysbetalipoproteinemia): A genetic disorder characterized by accumulation of remnant lipoproteins, resulting in elevated cholesterol and triglycerides and associated with premature atherosclerotic cardiovascular disease. The Friedewald equation significantly underestimates low-density lipoprotein cholesterol in this condition.

Very-low-density lipoprotein cholesterol (VLDL-C): A lipoprotein fraction that carries triglycerides in the blood.

Peer Reviewed Publications:

1. Chiurchiu V, Leuti A, Maccarrone M. Bioactive lipids and chronic inflammation: managing the fire within. Front Immunol. 2018;9:38.
2. Gladman DD, Charles-Schoeman C, McInnes IB, et al. Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase III and long-term extension studies. Arthritis Care Res (Hoboken). 2019;71(10):1387-1395.
3. Hegele RA. Approach to the adult patient with chylomicronemia. J Clin Endocrinol Metab. 2026;111(3):845-859.
4. Hansen TJ, Lucking SM, Miller JJ, et al. Standardized laboratory monitoring with use of isotretinoin in acne. J Am Acad Dermatol. 2016;75(2):323-328.
5. Roberts MC, Dotson WD, DeVore CS, et al. Delivery of cascade screening for hereditary conditions: a scoping review of the literature. Health Aff (Millwood). 2018;37(5):801-808.
6. Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141.

Government Agency, Medical Society, and Other Authoritative Publications:

1. Agarwala A, Dixon DL, Gianos E, et al. Dyslipidemia management in women of reproductive potential: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024;18(5):e664-e684.
2. Association for Diagnostics and Laboratory Medicine. ADLM guidance on direct LDL-C measurement: clinical indications and laboratory considerations. Clin Chem. 2024; 70(3):423-435.
3. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Epub. Published online March 13, 2026.
4. Cao J, Donato LJ, El-Khoury JM, et al. ADLM guidance document on the measurement and reporting of lipids and lipoproteins. J Appl Lab Med. 2024;9(5):1040-1056.
5. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2019; 139(25): e1082-e1143.
6. Jacobson TA, Maki KC, Orringer CE, et al. National Lipid Association Recommendations for patient-centered management of dyslipidemia: Part 2. J Clin Lipidol. 2015;9(6 Suppl):S1-122.e1.
7. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017; 23(Suppl 2):1-87.
8. Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022;145(9): e722-e759.
9. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021; 52(7):2021;52(7):e364-e467.
10. National Heart, Lung, and Blood Institute (NHLBI). Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. 2012. Available at: https://www.nhlbi.nih.gov/files/docs/guidelines/peds_guidelines_full.pdf. Accessed on January 13, 2026.
11. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Updated September 25, 2025. Available at: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv. Accessed on April 28, 2026.
12. Peterson AL, Ashraf AP, Bachman J, et al. Screening, diagnosis, and management of pediatric hypertriglyceridemia: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2026;46(4): e000195.
13. U.S. Preventive Services Task Force (USPSTF). Screening for lipid disorders in children and adolescents: recommendation statement. 2023. Available at: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lipid-disorders-in-children-screening. Accessed on April 27, 2026.
14. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia. J Am Coll Cardiol. 2021; 78(9):960-993.
15. Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019; 13(3):374-392.

1. American Heart Association. Available at: https://www.heart.org. Accessed on May 16, 2026.
2. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov. Accessed on May 16, 2026.
3. National Heart, Lung, and Blood Institute. Available at: https://www.nhlbi.nih.gov. Accessed on May 16, 2026.

Atherosclerotic Cardiovascular Disease
Calculated LDL-C
Cholesterol Testing
Direct LDL-C
Dyslipidemia
Familial Hypercholesterolemia
Friedewald Equation
HDL-C
LDL-C
Lipid Panel
Lipid Screening
Nonfasting Lipid Testing
Pediatric Lipid Screening
Total Cholesterol
Triglycerides

Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan’s or line of business’s members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only - American Medical Association